HGF/c-Met comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-22. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | For lyophilized powder; avoid repeated freeze-thaw. |
| Appearance | White to off-white powder | Common for lyophilized peptides. |
| Solubility | Soluble in water and aqueous buffers | Limited solubility in nonpolar solvents. |
| Typical analytical method | Reverse-phase HPLC and mass spectrometry | Used for purity and identity checks. |
| Typical purity specification | 95% or greater by HPLC area | Supplier values vary; not a biological potency measure. |
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
==== Prostaglandin E1 (PGE1) agonists ==== Alprostadil (Caverject; Prostaglandin E1) – prostaglandin E1 (PGE1) agonist – erectile dysfunction [129] Alprostadil alfadex (alprostadil alfadex complex; alprostadil-alpha-cyclodextrin; Edex; Prostaglandin E1-α-cyclodextrin complex; Prostandin; Prostavasin; Rigidur; Sugiran; Vasaprostan; Vasoprost; Viridal) – prostaglandin E1 (PGE1) agonist – erectile dysfunction [130] Alprostadil topical (Alprox-TD; Befar; Cold Chain Vitaros; Femprox; RayVa; Room Temperature Vitaros; Virirec; Vitaros; Vytaros; WC-3036) – prostaglandin E1 (PGE1) agonist – erectile dysfunction [131]
=== Esperanto === Since Esperanto allows word compounding, there are no limits on how long a word can theoretically become. An example is the 39-letter word oranĝ-kanton-pafil-limig-aktivul-malamanto, meaning "Orange County gun control activist hater". Such clusters are not considered good style (the 8-word alternative oranĝkantona malamanto de aktivuloj por limigo de pafiloj is more standard), but they are permissible under the rules of Esperanto grammar. Hyphens are optional in Esperanto compounds, so oranĝkantonpafillimigaktivulmalamanto is also technically a valid spelling. Disregarding compounding, conjugation, and affixes, the longest Esperanto word formally recognized by the Akademio de Esperanto is the 15-letter proper noun Konstantinopolo (Constantinople). The next longest recognized words are the following 13-letter words:
The motto of Schleswig-Holstein is "Up ewich ungedeelt" (Middle Low German: "Forever undivided", modern High German: "Auf ewig ungeteilt"). It goes back to the Treaty of Ribe (Danish: Ribe Håndfæstning German: Handfeste von Ripen) in 1460. Ripen (Ribe) is a historical small town in Northern Schleswig, nowadays Denmark. The anthem from 1844 is called "Wanke nicht, mein Vaterland" ("Don't falter, my fatherland"), but it is usually referred to with its first line "Schleswig-Holstein meerumschlungen" (i.e., "Schleswig-Holstein embraced by the seas") or "Schleswig-Holstein-Lied" (Schleswig-Holstein song). The old city of Lübeck is a UNESCO World Heritage Site.
=== Smoking cessation === Cytisine has been available in post-Soviet states as an aid to smoking cessation under the brand name Tabex from the Bulgarian pharmaceutical company Sopharma AD. In 1961, Bulgarian pharmacist Strashimir Ingilizov synthesized Tabex using the alkaloid Cytisine which was derived from the seeds of the yellow acacia (Cytisus laburnum), a European decorative shrub prevalent in Bulgaria and commonly referred to as "golden rain". It was first marketed in Bulgaria in 1964 and then became widely available in the Soviet Union. In Poland, it is sold under the brand name Desmoxan, and it is also available in Canada under the brand name Cravv. In June 2026, the U.S. Food and Drug Administration issued a complete response letter for Achieve Life Sciences' application to market cytisinicline for smoking cessation, citing deficiencies at a third-party manufacturing facility and unfinished product labeling. Its molecular structure has some similarity to that of nicotine, and it has similar pharmacological effects. Like the smoking cessation aid varenicline, cytisine is a partial agonist of nicotinic acetylcholine receptors (nAChRs). Cytisine has a short half-life of 4.8 hours. As a result, the extract provides smokers with satisfaction similar to smoking a cigarette, alleviating the urge to smoke and reducing the severity of nicotine withdrawal symptoms, while also reducing the reward experience of any cigarettes smoked.
== Diagnosis == In the early-onset form, an infant will present with poor feeding causing failure to thrive, or with difficulty breathing. The usual initial investigations include chest X-ray, electrocardiogram, and echocardiography. Typical findings are those of an enlarged heart with non-specific conduction defects. Biochemical investigations include serum creatine kinase (typically increased 10 fold) with lesser elevations of the serum aldolase, aspartate transaminase, alanine transaminase and lactic dehydrogenase. Diagnosis is made by estimating the acid alpha-glucosidase activity in either skin biopsy (fibroblasts), muscle biopsy (muscle cells), or white blood cells. The choice of sample depends on the facilities available at the diagnostic laboratory. In the late-onset form, an adult will present with gradually progressive arm and leg weakness, with worsening respiratory function. Electromyography may be used initially to distinguish Pompe from other causes of limb weakness. The findings on biochemical tests are similar to those of the infantile form, with the caveat that the creatine kinase may be normal in some cases. The diagnosis is by estimation of the enzyme activity in a suitable sample. On May 17, 2013, the Secretary's Discretionary Advisory Committee on Heritable Diseases in Newborns and Children (DACHDNC) approved a recommendation to the Secretary of Health and Human Services to add Pompe to the Recommended Uniform Screening Panel (RUSP). The HHS secretary must first approve the recommendation before the disease is formally added to the panel.
Sources: en.wikipedia.org
=== Films === Kung-Fu Master (1988) – directed by Agnès Varda Trop (peu) d'amour (1998) – directed by Jacques Doillon Mauvaises fréquentations (1999) – directed by Jean-Pierre Améris Mamirolle (2000) – directed by Brigitte Coscas Carrément à l'ouest (2001) – directed by Jacques Doillon Embrassez qui vous voudrez (2002) – directed by Michel Blanc Blanche (2002) – directed by Bernie Bonvoisin Saint Ange (2004) – directed by Pascal Laugier La Vida perra de Juanita Narboni (2005) – of Farida Benlyazid Sisters (2006) – directed by Douglas Buck Go Go Tales (2007) – directed by Abel Ferrara Boxes (2007) – directed by Jane Birkin and starring Birkin, Geraldine Chaplin, Michel Piccoli and Natacha Régnier Bazar (2009) – directed by Patricia Plattner and starring Bernadette Lafont Gigola (2010) – directed by Laure Charpentier Naked in London (2011) – directed by Mark Tierney Polisse (2011) – directed by Maïwenn Un enfant de toi (2012) – directed by Jacques Doillon Quasi a Casa (2024) - directed by Carolina Pavone
Methionine (symbol Met or M) () is an essential amino acid in humans. Compared to other amino acids, methionine has particularly decisive biosynthetic roles. It is the precursor to the amino acid cysteine and the pervasive methylation agent rSAM. Methionine is required for protein synthesis, which is initiated by N-formylmethionine-sRNA. Methionine was first isolated in 1921 by John Howard Mueller. It is encoded by the codon AUG. It was named by Satoru Odake in 1925, as an abbreviation of its structural description 2-amino-4-(methylthio)butanoic acid.
Addiction is a serious risk with heavy recreational amphetamine use, but is unlikely to occur from long-term medical use at therapeutic doses. Very high doses can result in psychosis, which rarely occurs at therapeutic doses even during long-term use. Recreational doses are generally much larger than prescribed therapeutic doses and carry a far greater risk of serious side effects. Amphetamine belongs to the phenethylamine class. It is also the parent compound of its own structural class, the substituted amphetamines, which includes prominent substances such as bupropion, cathinone, MDMA, and methamphetamine. As a member of the phenethylamine class, amphetamine is also chemically related to the naturally occurring trace amine neuromodulators, specifically phenethylamine and N-methylphenethylamine, both of which are produced within the human body. Phenethylamine is the parent compound of amphetamine, while N-methylphenethylamine is a positional isomer of amphetamine that differs only in the placement of the methyl group.
As described by Jeong et al., compared with other do novo peptide sequencing tools, which works well on only certain types of spectra, UniNovo is a more universal tool that has a good performance on various types of spectra or spectral pairs like CID, ETD, HCD, CID/ETD, etc. It has a better accuracy than PepNovo+ or PEAKS. Moreover, it generates the error rate of the reported peptide sequences. Ma published Novor in 2015 as a real-time de novo peptide sequencing engine. The tool is sought to improve the de novo speed by an order of magnitude and retain similar accuracy as other de novo tools in the market. On a Macbook Pro laptop, Novor has achieved more than 300 MS/MS spectra per second. Pevtsov et al. compared the performance of the above five de novo sequencing algorithms: AUDENS, Lutefisk, NovoHMM, PepNovo, and PEAKS . QSTAR and LCQ mass spectrometer data were employed in the analysis, and evaluated by relative sequence distance (RSD) value, which was the similarity between de novo peptide sequencing and true peptide sequence calculated by a dynamic programming method. Results showed that all algorithms had better performance in QSTAR data than on LCQ data, while PEAKS as the best had a success rate of 49.7% in QSTAR data, and NovoHMM as the best had a success rate of 18.3% in LCQ data. The performance order in QSTAR data was PEAKS > Lutefisk, PepNovo > AUDENS, NovoHMM, and in LCQ data was NovoHMM > PepNovo, PEAKS > Lutefisk > AUDENS. Compared in a range of spectrum quality, PEAKS and NovoHMM also showed the best performance in both data among all 5 algorithms.
Sources: en.wikipedia.org
Soldiers were expected to carry their grain rations and cooking utensils in addition to their weaponry, with their backpacks potentially weighing as much as eighty pounds (36 kg). Without the hindrance of oxen and carts, this enabled Macedonian armies to move faster than their opponents. The grain provided to Macedonian soldiers would be wheat, barley, or millet, which were available throughout Asia and could be stored indefinitely when dried. The soldiers would use grinding mills carried by servants to turn the grain into flour, which could then be made into bread, biscuits, and porridge. They also ate various kinds of dried fruits such as dates and figs, which were readily available throughout much of Asia. Whenever possible, they would eat dried meat, salted fish, and shellfish. In ancient China, soldiers of the Han dynasty ate primarily millet and other grains such as wheat, rice, sorghum, etc. Grains could be eaten as a porridge, boiled, made into a bread or flatbread, smashed and fried in a manner similar to modern fried rice and fried noodles, etc. According to Zhao Chongguo, a military commander of the Han dynasty who served in the first century BC, a force of 10,281 men required 27,363 hu of grain and 308 hu of salt each month, requiring a convoy of 1,500 carts for transport. One hu is equivalent to 19.968 liters, meaning that each soldier would have required 51.9 liters of grain and 0.6 liters of salt per month. Another document at Juyan suggests 3.2 hu, or 63.8 liters, of grain.
The proton–proton chain is more prominent in stars the mass of the Sun or less. This difference stems from temperature dependency differences between the two reactions; pp-chain reaction starts at temperatures around 4×106 K (4 megakelvins), making it the dominant energy source in smaller stars. A self-maintaining CNO chain starts at approximately 15×106 K, but its energy output rises much more rapidly with increasing temperatures so that it becomes the dominant source of energy at approximately 17×106 K. The Sun has a core temperature of around 15.7×106 K, and only 1.7% of 4He nuclei produced in the Sun are born in the CNO cycle. The CNO-I process was independently proposed by Carl von Weizsäcker and Hans Bethe in the late 1930s. The first reports of the experimental detection of the neutrinos produced by the CNO cycle in the Sun were published in 2020 by the BOREXINO collaboration. This was also the first experimental confirmation that the Sun had a CNO cycle, that the proposed magnitude of the cycle was accurate, and that von Weizsäcker and Bethe were correct.
From the perspective of its commercial promoters, scientific breakthroughs, industrial commitment, and official support were finally coming together, and biotechnology became a normal part of business. No longer were the proponents for the economic and technological significance of biotechnology the iconoclasts. Their message had finally become accepted and incorporated into the policies of governments and industry.
Sources: en.wikipedia.org
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.
Reverse-phase HPLC can estimate purity, while mass spectrometry helps confirm molecular mass. These methods do not prove biological effects. Lot-specific certificates may provide additional data.
It is not an approved medicine in major jurisdictions. Depending on the country and marketing claims, it may be treated as a research chemical or unapproved substance. Import and sale rules vary.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.